retatrutide type 2 diabetes trial results 2024 ESC 2024: improves lipid and cardiovascular risk profile in Phase II Retatrutide improves blood sugar and

Dosing fundamentals Administration: Once weekly subcutaneous injection Same day each week (consistency matters) Preferably at the same time of day Half-life: Approximately 6 days, supporting weekly dosing Dose escalation: Every 4 weeks, unless: Side effects require holding current dose Individual tolerance suggests faster/slower progression Healthcare provider recommends adjustment Clinical trial doses tested The Phase 2 obesity trial tested multiple dosing arms: Key insight: 8 mg produces nearly the same results as 12 mg with fewer side effectsmaking it a potential "sweet spot" for many users

That's a metabolic combination we haven't seen before in a single molecule

Statistics in Medicine

The compound has a half-life of approximately six days, which allows for convenient once-weekly dosing